India Pharma Outlook Team | Wednesday, 23 September 2026
Amgen eyes a wide-open market after its experimental autoimmune drug delivers a clear late-stage trial win in Sjogren's disease.
The company reports that dazodalibep meets the main goal of reducing disease activity and posts statistically significant and clinically meaningful improvement at week 48.
Sjogren's disease attacks the body's moisture-producing glands and currently has no approved treatments in the United States.
This leaves a substantial unmet need that Amgen now positions itself to address. Shares rise 4 percent on the news as investors weigh the commercial potential of a first-in-class option in a condition that affects roughly 1 percent of the global population and predominantly women.
Novartis and Johnson & Johnson also pursue candidates, yet none have reached approval. Amgen therefore steps into a space defined by high disease burden and limited options.
Amgen announces that dazodalibep produces statistically significant and clinically meaningful improvement in patients with moderate-to-severe disease activity at week 48. The drug targets an autoimmune condition that causes extensive dryness of the eyes, mouth and other parts of the body along with fatigue and chronic pain.
Safety data support continued development. Most adverse events remain mild to moderate. Few patients discontinue treatment during the trial. William Blair analyst Matt Phipps calls the results encouraging. He notes the high risk and development challenges in Sjogren's disease, including historically elevated placebo response rates.
Analysts still flag that several investor-relevant details remain absent from the initial readout. Full trial results will require comparison against Novartis' ianalumab once Amgen presents the complete data set at an upcoming medical meeting.
Also Read: How Can India Pharma Bridge the Gap Between Innovation and Access
Amgen also runs a separate late-stage trial called OASIZ 303. This study focuses on Sjogren's patients with moderate-to-severe symptom burden. Results are expected in the fourth quarter of 2026.
Phipps expects two positive late-stage studies will be needed for FDA approval in Sjogren's disease. Amgen will likely outline regulatory and filing plans after the OASIZ 303 readout. The company plans to present detailed data from the current trial at a forthcoming medical conference.
Key points from the announcement:
Sjogren's disease affects about 1 percent of the global population and predominantly women, according to the National Institutes of Health. The absence of any approved therapy in the United States creates a wide-open commercial opportunity.
Novartis and Johnson & Johnson continue their own development programs, yet neither has secured approval. Amgen therefore advances with a positive late-stage result in a field still lacking established treatment options.
The trial success positions dazodalibep as a potential first mover if the second study also succeeds and regulators grant approval. Investors will watch the detailed data presentation and the OASIZ 303 outcome for confirmation of both efficacy and durability. Until then, Amgen holds the clearest positive late-stage signal in a market defined by high unmet need and limited competition.
.jpg)
